Why carry out this study?
|
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the placebo and tafamidis arms of ATTR-ACT did not achieve median overall survival by the completion of the study at 30 months. A statistical extrapolation method was developed to estimate their survival beyond the 30-month trial duration. |
What was learned from the study?
|
Findings from the survival extrapolation analysis suggest that at least 50% of patients receiving tafamidis would survive for approximately 53 months, compared to 35 months for those receiving placebo, providing further support for the efficacy of tafamidis in ATTR-CM. |
Introduction
Methods
Results
Model | Placebo | Pooled tafamidis | Tafamidis 80 mg | Tafamidis 20 mg | ||||
---|---|---|---|---|---|---|---|---|
AIC | BIC | AIC | BIC | AIC | BIC | AIC | BIC | |
Exponential | 770.26 | 773.44 | 854.33 | 857.91 | 587.82 | 590.99 | 268.27 | 270.74 |
Weibull | 754.50 | 760.86 | 852.85 | 860.00 | 586.89 | 593.23 | 269.61 | 274.57 |
Gammaa | 755.92 | 762.27 | 852.45 | 859.60 | 586.70 | 593.04 | 269.44 | 274.40 |
Log-logistic | 756.27 | 762.62 | 851.90 | 859.05 | 586.48 | 592.82 | 269.11 | 274.06 |
Log-normal | 765.21 | 771.57 | 850.99 | 858.15 | 587.05 | 593.39 | 267.74 | 272.69 |
Gompertz | 754.16 | 760.51 | 855.10 | 862.26 | 588.31 | 594.65 | 270.24 | 275.19 |
Generalized gamma | 755.80 | 765.33 | 852.94 | 863.67 | 588.43 | 597.94 | 268.61 | 276.04 |
Generalized F | 757.77 | 770.47 | 854.94 | 869.24 | 590.30 | 602.99 | 270.61 | 280.52 |